Akut mieloid leukémia (AML): vizsgálatok itt: Olaszország

In Olaszország 61 Also abroad 761

61 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.

1. fázisNot yet taking people in Olaszország
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
Where
Bologna, Ravenna
Életkor
18 év and over
People
126 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07929740 · EU 2025-524332-19-00
3. fázisTaking people
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Where
Ancona, Bergamo, Castelfranco Veneto, Florence, Genoa, Milan, Palermo, Perugia, Pescara, Ravenna, Rome, San Giovanni Rotondo
Életkor
18 év and over
People
875 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00
1. fázisTaking people
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Where
Bergamo, Pisa, Rozzano
Életkor
18 év and over
People
78 worldwide
Run by
Genmab
See details and how to joinNCT07384715 · EU 2025-523101-15-00
3. fázisTaking people
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Bergamo, Bologna, Brescia, Meldola, Milan, Pavia, Perugia, Pesaro, Ravenna, Reggio Calabria, Rozzano, San Giovanni Rotondo, Torino
Életkor
18 év and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00
No phaseTaking people
The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial
Where
Bari, Roma, Verona
Életkor
18 év to 75 év
People
75
Run by
Gruppo Italiano Malattie EMatologiche dell'Adulto
See details and how to joinNCT07912684
3. fázisTaking people
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Where
Alessandria, Ascoli Piceno, Brindisi, Florence, Lecce, Milan, Monza, Pavia, Pesaro, Reggio Calabria, Roma, San Giovanni Rotondo
Életkor
18 év to 75 év
People
366 worldwide
Run by
Priothera SAS
See details and how to joinNCT05429632
3. fázisTaking people
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Where
Roma, Vicenza
Életkor
18 év to 71 év
People
150 worldwide
Run by
Quetzal Therapeutics
See details and how to joinNCT07504458 · EU 2025-524810-28-00
No phaseTaking people
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Where
Ancona, Bologna, Brescia, Brindisi, Busto Arsizio, Castelfranco Veneto, Como, Cremona, Cuneo, Ferrara, Florence, Genova, Meldola, Milan, Naples, Novara, Padova, Palermo, Perugia, Pescara, Ravenna, Rimini, Roma, Salerno, Torino, Vicenza
Életkor
6 év and over
People
4000 worldwide
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06459024
3. fázisTaking people
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Where
Ancona, Bologna, Brescia, Busto Arsizio, Castelfranco Veneto, Florence, Genoa, Meldola, Milan, Naples, Padova, Palermo, Pavia, Perugia, Pescara, Piacenza, Ravenna, Rimini, Rome, San Giovanni Rotondo, Siena, Turin, Vicenza
Életkor
18 év and over
People
339 worldwide
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06713837 · EU 2024-514517-35-00
1/2. fázisTaking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Bologna, Ravenna
Életkor
16 év and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
3. fázisTaking people
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Where
Bologna, Milan, Rome, Turin
Életkor
18 év and over
People
180 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 · EU 2024-512753-24-00
3. fázisTaking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Alexandria, Bari, Bergamo, Bologna, Brescia, Candiolo, Florence, Genoa, Meldola, Milan, Modena, Monza, Naples, Palermo, Pavia, Perugia, Pesaro, Pisa, Reggio Calabria, Reggio Emilia, Rimini, Rome, Turin, Udine
Életkor
12 év and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
No phaseTaking people
This Study Aims to Improve the Stratification of Patients With Acute Myeloid Leukemia to Enable More Personalized and Effective Treatments, and to Identify and Functionally Validate, at the Single-cell Level, Biomarkers That Can Predict Response to Venetoclax.
Where
Milan
Életkor
18 év and over
People
420
Run by
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
See details and how to joinNCT07874100
3. fázisTaking people
Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to customize therapy.
Where
Alexandria, Bari, Bologna, Brescia, Ferrara, Florence, Latina, Lecce, Novara, Padova, Palermo, Pavia, Perugia, Pescara, Piacenza, Ravenna, Reggio Calabria, Reggio Emilia, Rionero in Vulture (PZ), Rome, Salerno, Sassari, Siena, Tricase, Turin, Viterbo, Ospedale Valduce, ULSS3 SERENISSIMA - Ospedale dell'Angelo di Mestre
Életkor
18 év and over
People
172
Run by
Fondazione G.I.M.Em.A Franco Mandelli Ets
See details and how to joinNCT04174612 · EU 2023-505901-17-00
1/2. fázisTaking people
CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults
Where
Bergamo, Monza
Életkor
6 hónap to 75 év
People
18
Run by
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
See details and how to joinNCT07877610
3. fázisTaking people
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Where
Alexandria, Ascoli Piceno, Bergamo, Bologna, Brescia, Catania, Milan, Modena, Naples, Perugia, Ravenna, Rome, Rozzano, Siena, Trieste, Turin, Vicenza
Életkor
18 év and over
People
1300 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07007312 · EU 2025-521314-25-00
1/2. fázisTaking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Bologna, Brescia, Genova, Milan, Monza, Naples, Pavia, Rome, Torino
Életkor
1 év to 17 év
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
1/2. fázisTaking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Bologna, Meldola, Milan, Rome, Vicenza
Életkor
30 nap and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
1. fázisTaking people
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Where
Monza, Rome
Életkor
0 év to 21 év
People
20 worldwide
Run by
PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00
2/3. fázisTaking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
Bologna, Florence, Milan, Novara, Ravenna, Rome, Turin
Életkor
18 év and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
1. fázisTaking people
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Where
Rome
Életkor
6 hónap to 17 év
People
18 worldwide
Run by
AbbVie
See details and how to joinNCT07306832
4. fázisTaking people
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Where
Bologna, Busto Arsizio, Milan, Modena, Novara, Padova, Perugia, Pescara, Ravenna, Rimini, Rome
Életkor
18 év and over
People
365 worldwide
Run by
Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
2. fázisTaking people
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RVU120 in Combination with Venetoclax in Participants with Acute Myeloid Leukemia Who Failed Prior Therapy with Venetoclax and a Hypomethylating Agent (RIVER-81)
Where
Ancona, Bologna, Brescia, Lecce, Meldola, Ravenna, Rome, Rozzano, Turin
Életkor
18 év and over
People
191 worldwide
Run by
Ryvu Therapeutics S.A.
See details and how to join2023-505911-19-00 · EU 2023-505911-19-00
2. fázisTaking people
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Where
Ancona, Bologna, Brescia, Lecce, Meldola, Ravenna, Roma, Rozzano, Turin
Életkor
18 év and over
People
98 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06191263
2. fázisCsak meghívásos
RVU120 Rollover Study
Where
Bari
Életkor
18 év and over
People
14 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00